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Abstract: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood
and is characterized by an often insidious onset and a chronic relapsing–remitting course, once
diagnosed. With successive flares of joint inflammation, joint damage accrues, often associated
with pain and functional disability. The progressive nature and potential for chronic damage and
disability caused by JIA emphasizes the critical need for a prompt and accurate diagnosis. This article
provides a review of recent studies related to diagnosis, monitoring and management of JIA and
outlines recent novel tools and techniques (infrared thermal imaging, three-dimensional imaging,
accelerometry, artificial neural networks and fuzzy logic) which have demonstrated potential value in
assessment and monitoring of JIA. The emergence of novel techniques to assist clinicians’ assessments
for diagnosis and monitoring of JIA has demonstrated promise; however, further research is required
to confirm their clinical utility.
Keywords: juvenile idiopathic arthritis; rheumatoid arthritis; artificial intelligence; thermal imaging;
accelerometry; fuzzy logic
1. Introduction
Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations
for Rheumatology (ILAR) as arthritis of unknown aetiology, starting before the sixteenth
birthday, lasting longer than six weeks, with all other diagnoses excluded [1]. Arthritis itself
is defined as swelling or effusion, increased warmth and/or painful limited movement
with or without tenderness [2,3].
The JIA diagnosis encompasses distinct sub-classifications, defined by the ILAR in
2001 to include systemic-onset arthritis, oligoarthritis, polyarthritis rheumatoid factor posi-
tive, polyarthritis rheumatoid factor negative, psoriatic arthritis, enthesitis-related arthritis
and undifferentiated arthritis [1]. This classification system has faced criticism as there is
increasing evidence that some of these categories are more heterogenous and may be more
accurately defined by a new system [4]. In 2019, the Paediatric Rheumatology Interna-
tional Trial Organization (PRINTO) began the verification process for a new classification
system [4].
JIA is the most common rheumatic disease of childhood, with an average prevalence
of 70 in 100,000 in Europe [5]. The data on the prevalence of JIA are varied, depending
on disease classification, geographical area and study design and have been reported to
vary between 3.8 to 400 cases per 100,000 worldwide [2]. JIA more commonly affects
females than males (>2:1); however, this distribution varies within the disease classification
system [6]. The age of onset of JIA also varies significantly between different subtypes; for
example, the median age of presentation of systemic-onset arthritis has been reported as
2 years [7], whereas for enthesitis-related arthritis, this has been reported as 11 years [6].
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JIA may affect any joint and frequently causes extra-articular inflammation (e.g.,
uveitis). When children and young people are being assessed for arthritis, it is important
that a thorough and careful examination is undertaken, as some joints, e.g., the temporo-
mandibular joint (TMJ) and hip joint, are unlikely to demonstrate signs of swelling. The
involvement of TMJ in JIA was recognized in 1897 [8]. Diagnostic imaging is particularly
important in assessing certain joints such as TMJ [9]. Avoiding delay in diagnosis of
arthritis in these joints is important, as joint damage can result in functional disability; for
example, the functional implications of TMJ arthritis include difficulty in eating, pain with
talking and alterations to the facial appearance [10]. Further reviews and discussions of
TMJ arthritis can be found in other articles [11,12].
In the following sections, the methodology used to prepare the article, an overview of
JIA as a medical condition together with the developments to diagnose and monitor JIA
are provided.
2. Methodology
The methodology used to prepare this article involved thorough literature searches,
using the electronic database MEDLINE (via Ovid), and the search was also cross-checked
on PubMed and Google Scholar to ensure no key articles were missed. The key words used
in the searches were as follows:
• JIA and rheumatoid arthritis,
• Aetiology of JIA,
• Clinical presentation of JIA,
• JIA diagnosis,
• Differential diagnosis of JIA,
• JIA management,
• Natural history of JIA,
• JIA and imaging modalities,
• Infrared thermal imaging and JIA,
• Three-dimensional imaging and JIA,
• JIA and accelerometry,
• JIA and inertia measurement unit,
• JIA and joint movement measurement,
• Artificial intelligence and JIA,
• Artificial neural networks and JIA,
• Machine learning and JIA,
• Fuzzy logic and JIA.
The search strategy aimed to identify and include articles that covered the diagnosis
of JIA and more specifically articles that identified current and novel tools available to
assist with the diagnosis of JIA. Articles were carefully screened to select those most
representative of research in the field. These articles were then selected according to
their relevance, publication in a reputable journal and any research focusing on only one
subtype of JIA was excluded. Duplicate articles and articles not available in English were
excluded, and more recently published articles were prioritized. Articles with overlapping
information were reduced to the most representative to provide an accurate summary of
the subject matter.
3. JIA and Rheumatoid Arthritis
JIA shares both clinical and pathological similarities with adult-onset rheumatoid arthritis
(RA); however, they remain distinct conditions. Like JIA, RA is an inflammatory progressive
disease that, untreated, can lead to joint destruction and disability [13]. Both conditions also
have a complex genetic component involving human leukocyte antigen (HLA) [14]. However,
RA is a much more homogenous condition than JIA, as it is classed as a single disease with
different clinical manifestations as opposed to JIA, where subtypes are diagnosed as separate
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entities [14]. RA also tends to have worse disease outcomes compared to JIA, which has
varied outcomes depending on subtype and severity of disease [14].
4. Aetiology of JIA
The exact pathogenesis of JIA remains unclear, though it is widely thought to be caused
by an immunogenic mechanism resulting from both genetic and environmental factors [15].
One specific genetic association linked to JIA is found in the HLA region. HLA-A2 shows
associations with early-onset disease, HLA-B27 is associated with enthesitis-related arthritis
and other subtypes of JIA are associated with specific alleles of the HLA gene [2].
Possible environmental stimuli include infection, childhood antibiotics, maternal
pregnancy, smoking, gut microbes, stress and trauma [2,15]. The genetic component of JIA
is thought to be significant as monozygotic twin concordance of JIA is between 25% and
40%, showing 250–400 times increase over population prevalence, and sibling concordance
is 15–30 times above population prevalence [2]. The developing opinion that JIA is a
more heterogenous disease than previously thought suggests causation is likely to be
multifactorial [16].
The immunogenic mechanism of JIA is believed to be mediated by chemokines that
selectively attract Type 1 Helper (Th1) T-cells, resulting in the cell mediated production
of proinflammatory cytokines such as interleukin-2 (IL-2), interferon-gamma and tumour
necrosis factor-alpha (TNF-alpha) [2].
5. Clinical Presentation of JIA
Chronic inflammation of the joints presents as synovitis, causing a build-up of synovial
fluid and thickening of the synovial lining. Histologically, there is hyperplasia of the lining
of the synovium and infiltration of the sub-lining with various inflammatory cells. This
chronic inflammatory process leads to the formation of pannus which causes cartilage
and bone erosions and consequent joint damage [17]. These pathophysiological changes
present clinically as a painful, red, swollen joint(s) with limited range of movement and, if
the arthritis is prolonged, potential for joint deformities and growth disturbances [18].
Joint involvement in JIA usually presents as pain, swelling and stiffness of joints
lasting more than 30 min. Stiffness is typically worse in the morning and relieved by
movement [2]. The child’s developmental age at presentation may affect the clinical picture
due to differences in communication ability; for example, using a limb in a different way,
or development of a limp, may be the only sign(s) in younger children [3]. The onset of
JIA often takes an insidious course which can result in a significant time period between
onset of first symptom and diagnosis. There is also a risk of misdiagnosis, as JIA can
closely resemble other conditions. Variation from the typical presentation of JIA can further
complicate diagnosis [15].
The clinical presentation of JIA also varies depending on JIA sub-type. Children with
systemic or polyarticular disease may present with more varied symptoms of fatigue, fever,
weight loss or growth failure [3].
JIA can also cause a number of extra-articular manifestations, and these typically vary
depending on the specific sub-type. For example, systemic arthritis may manifest with a
fever and a rash as well as arthritis. Other extra-articular manifestations include dactylitis,
lymphadenopathy and pericarditis. A frequently occurring extra-articular manifestation
in other sub-types of JIA is chronic, anterior, non-granulomatous uveitis (iridocyclitis),
which is most common in the oligoarthritis subtype (21%) but also occurs with varying
incidence in other JIA subtypes including polyarticular disease. Uveitis may be present at
the time of diagnosis (it can occur prior to the onset of arthritis), or it may develop during
the course of the disease; therefore, patients should be screened regularly to prevent delay
in diagnosis and reduce the risk of visual impairment [19]. The presence of extra-articular
manifestations further increases the challenge of achieving an early accurate diagnosis.
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6. Diagnosis of JIA
JIA is a diagnosis of exclusion. Thorough history-taking and clinical examination
are imperative. The paediatric Gait Arms Legs Spine (pGALS) examination is a validated
screening tool to help identify musculoskeletal abnormalities such as inflammation [17].
This screening tool is quick and easy to perform and has good sensitivity and specificity
when compared with the regular clinical assessment performed by a consultant [17,20].
However, studies have shown that current examination techniques may underestimate
joint inflammation, and that some asymptomatic joints show histological evidence of
synovial inflammation, demonstrating the presence of subclinical inflammation [21]. The
underestimation of joint inflammation by examination could be due to the subjectivity of
a clinical examination, and the insidious onset of JIA that may not initially be clinically
detectable. Therefore, relying on clinical examination alone may lead to delayed diagnoses
and delayed or sub-optimal treatment. A clinical examination of 1667 joints identified
104 joints with inflammation, but ultrasound of the same joints identified 167 joints with
inflammation, demonstrating the underestimation of inflammation by clinical examination
alone [21]. A further study made comparison between physical examination and contrast-
enhanced MRI and found that subclinical synovitis was present in 35.9% of cases of
presumed clinically inactive JIA [22].
There is no specific diagnostic test for JIA [23]; however, blood tests can be used to
exclude other diseases, assist with understanding the subtype of JIA or to help guide
future treatment and management. The monitoring of non-specific inflammatory markers
(erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) can aid the diagnosis
and monitoring of JIA. [17]. Certain tests can aid the specific subtype diagnosis of JIA
such as anti-nuclear antibodies (ANA), rheumatoid factor (RF) and anti-cyclic citrullinated
peptide antibody (Anti-CCP) [2]. These tests, however, are not specific for JIA, and levels
can be raised in healthy children or by other non-JIA diseases, so their results should be
interpreted with caution [17]. The use of specific biomarkers has also been explored to aid
the diagnosis of JIA, particularly in systemic-onset arthritis. However, due to the complex
immune reaction, many unique biomarkers have been identified, though none have been
recently validated for use [24].
Imaging is regularly used as a diagnostic adjunct in JIA to support clinical evalua-
tion [25]. Plain radiographs have previously been the traditional first-line imaging of choice.
However, increasingly more varied imaging techniques are being employed to detect active
inflammation such as musculoskeletal ultrasonography and contrast enhanced magnetic
resonance imaging (MRI) [25]. These imaging tools contribute greater diagnostic value than
plain radiograph imaging, but they are relatively expensive and remain less accessible than
is needed for routine use in the outpatient clinic setting. These tools may be particularly
useful in assessing joints such as the TMJ and hip, which are harder to assess clinically
(as swelling and warmth are rarely appreciated) compared with joints such as the knee
or ankle. Despite these tools, there is still no definitive diagnostic test for JIA; therefore,
there is a pressing need to develop novel diagnostic techniques to improve the speed and
accuracy of diagnosis.
7. Differential Diagnoses
The early diagnosis of JIA is critical to avoid permanent damage and disability [26],
but this can often be challenging due to the numerous possible differential diagnoses.
An important differential diagnosis of a single swollen joint is septic arthritis; in
this case, the presentation would likely include fever and more severe joint pain. This
diagnosis can usually be excluded by joint aspiration with microbiological examination and
specific antigen testing. Any presentation of inflammatory joint disease with symptoms
atypical to JIA or with systemic symptoms should raise suspicion of malignancy. The
early presentation of JIA and malignancy can be very similar; therefore, if malignancy is
suspected, early investigations to exclude this differential (such as bone marrow biopsy or
further imaging) are essential to rule it out [17].
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Many other conditions and normal variants can mimic JIA, which adds to the diag-
nostic challenge when considering this diagnosis of exclusion.
8. Management of JIA
Once diagnosed, the early treatment of JIA is critical to optimize the potential for
medically induced disease remission and to avoid further joint damage. The optimal
management of JIA requires the involvement of a broad multidisciplinary team including,
but not limited to, a consultant paediatric rheumatologist, specialist nurse, physiotherapist,
occupational therapist, ophthalmologist, psychologist and general practitioner [23,27].
Treatment involves both pharmacological and non-pharmacological interventions, and
prompt referral to a tertiary specialist service is essential to confirm diagnosis and initiate
proactive treatment [23].
The pharmacological interventions for JIA begin with simple treatments and can
progress to more complex therapies if patients do not respond adequately [6]. First-line
treatment is with nonsteroidal anti-inflammatory drugs (NSAIDs); these are frequently
used agents in the treatment of JIA [6,28]. Intra-articular corticosteroid injections are
indicated in all sub-types of JIA for local inflammation relief where the disease can be
localized to individual joints [6].
More intensive treatment options include systemic glucocorticoids (e.g., prednisolone),
which are indicated to treat certain extra-articular manifestations [27], widespread joint
involvement and active systemic-onset JIA. However, they are less commonly used now
due to their extensive adverse event profile and the development of disease modifying
anti-rheumatic drugs (DMARDs) and biologic drugs [6]. Both DMARDs and biologic drugs
can actively slow or halt the progression of JIA and prevent the development of long-term
morbidity [6].
The development of new biologic drugs over the past 20 years has significantly
improved disease course and outcomes [2]. These drugs include monoclonal antibodies,
receptor antagonists or soluble cytokine receptors [6] and are used to treat JIA which
has not responded adequately to DMARD treatment, or where individuals are intolerant
of DMARDs. The treatment of systemic-onset JIA specifically has developed to include
targeted therapies for interleukin-1 and interleukin-6, as these cytokines are recognized as
playing an important role in the development of inflammation [29].
Non-pharmacological management strategies are also involved in disease manage-
ment; these include, but are not limited to, nutritional monitoring, increased calcium intake,
physiotherapy, aquatic exercise and orthotics [23]. Exercise therapy is also helpful for
children with JIA; A 2018 systematic review found that a structured, physical therapy-led
exercise program focusing on strength and flexibility may have a beneficial impact on
activity outcomes in JIA [30]. Alongside active treatment of JIA, ongoing monitoring for
extra-articular complications is essential. Patients should be regularly screened by an
ophthalmologist due to the risk of uveitis and associated eye complications [23].
9. Natural History of JIA
The reported prognosis of JIA is unclear, and there are varied and conflicting published
data on the topic. Previous studies have shown that only 40–60% of patients achieve clinical
remission or inactive disease at follow up [16]. The duration of remission achieved is also
highly variable, with one study showing that only 36% of cases of clinical remission lasted
two years off medication, and only 6% of cases of clinical remission lasted for five years [31].
Their study involved 437 JIA patients and examined 878 total episodes of active disease.
However, it did not include analysis of how treatment type affects disease course, and this
could be a topic for future research. This was also a long duration retrospective study and,
as the diagnostic classification of JIA has changed over this time, the classification system
used in this study may not be entirely transferable to the classification used today [31].
The diagnosed sub-type of JIA has a significant effect on predicted disease outcomes.
Oligoarthritis is the most likely sub-type to achieve clinical remission, and RF-positive
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polyarticular JIA is the least likely to achieve remission [16,31]. Systemic-onset JIA is
associated with the worst prognosis, with 30% of patients suffering from chronic polyarthri-
tis resulting in morbidity [7]. Systemic-onset JIA has a significant non-articular disease
component that has a large impact on disease morbidity.
The damage caused by JIA can affect patients into adulthood and cause chronic
disability. Up to half of young adults will continue to have active disease, and up to one
third will have chronic disability into adulthood [3]. The long-term damaging effects on
bone and joint development include local growth disturbances at the sites of inflammation.
This can result in either overgrowth or undergrowth, thereby resulting in limb length
discrepancies [16]. The extra-articular uveitis manifestation of JIA can also have long-term
damaging sequalae such as glaucoma, cataracts and blindness [2].
Despite the low rate of clinical remission achieved in JIA, there has been an improve-
ment in functional disease outcomes over the past decade. The proportion of patients that
develop profound functional disability ranges between 2.5 and 10% [16]. There are several
predictors of poor outcome that can help identify those susceptible to serious disease.
These include greater severity or extent of arthritis at onset, symmetrical disease, early
wrist or hip involvement, presence of RF, persistent active disease and early radiographic
changes [16]. Shorter disease duration prior to treatment and aggressive therapy have also
been shown to improve disease outcomes [2].
Increasing evidence has demonstrated that early and aggressive treatment of JIA is asso-
ciated with better long-term disease outcomes. This evidence offers the suggestion that there
is a “window of opportunity” to begin treatment in order to achieve the best results [26,32].
This theory adds to the importance of achieving a prompt and accurate diagnosis of JIA so
that early treatment can commence, and disease outcomes can be optimized.
There are also immediate effects on the general wellbeing of patients with JIA, irre-
spective of their disease status. These effects have negative psychosocial and physical
consequences [33]. Direct physical consequences include obesity and atherosclerosis, and
psychosocial impacts include chronic fatigue and pain, as well as functional impairment
and decreased health-related quality of life [33]. These direct impacts of JIA can greatly
affect the functioning and wellbeing of children affected with the condition. For example,
a study showed that school-age children with JIA took part in fewer sports clubs and
reported physical and psychological barriers to sports engagement [34].
10. Imaging
The serious consequences of untreated JIA highlight the importance of a prompt and
accurate diagnosis. Current diagnostic methods centre around a detailed clinical history
and examination supported, where appropriate, by various imaging techniques.
Plain radiographs historically have been the first-line imaging option in JIA. They
are particularly useful for the exclusion of differential diagnoses involving bone such as
fracture, tumour and osteomyelitis [35]. Radiographs can also demonstrate signs such as
soft tissue swelling, periarticular osteopenia, epiphyseal remodelling and widening, which
can all be indicators of JIA [17]. However, in the early stages of JIA, radiographs are often
normal [17], and they have also been shown to be poor in identifying active synovitis [27].
Due to the importance of early diagnosis of JIA, the identification of early non-erosive
joint changes has become a greater priority, for which plain radiographs are not the most
suitable tool [36].
Ultrasound is a quick, cost-effective and safe imaging alternative to aid the diagnosis
of JIA [17]. Ultrasound can detect synovial, cartilage and bone abnormalities earlier
than conventional radiography and has demonstrated a higher sensitivity than clinical
examination [37]. Ultrasound has also been shown to detect subclinical synovitis, which
clinical examination alone may not detect [37], thereby enabling earlier diagnosis and
earlier commencement of treatment. However, there is a lack of standard references for
paediatric joint ultrasound, which limits the diagnostic value of this technique. It is also
unclear whether ultrasound can differentiate between true erosions and normal surface
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irregularities, especially in small joints, again limiting its diagnostic utility [38]. Another
limitation of ultrasound investigation is that it is time consuming and relies on operator
interpretation and experience, which can be varied [39].
Magnetic resonance imaging (MRI) is a highly sensitive imaging tool for detecting joint
inflammation [38]. Contrast-enhanced MRI (CE-MRI) can distinguish between clinically
active and inactive JIA, which alternative investigative methods may fail to discriminate
between. A study investigated MRI data sets from 146 patients with suspected or diagnosed
JIA and found that MRI could differentiate clinically active and inactive disease states by
identifying synovial hypertrophy [22]. The study identified that a third of the patients
who were clinically presumed to have inactive JIA showed signs consistent with active
synovitis on MRI. This demonstrates the utility of CE-MRI in detecting subclinical synovitis.
Despite the clinical utility of MRI, its use is limited by high cost, ability to assess only a
single joint or few joints per scan and the requirement for sedation in younger children [38].
There are also additional considerations for the clinician when requesting CE-MRI, such as
procedural anxiety.
Magnetic resonance imaging is particularly valuable for aiding assessment of TMJ
arthritis in JIA, as it can image both soft tissue and bone and allows the assessment
of changes to the joint over time [40,41]. A recent study of 96 patients with JIA and
20 non-JIA controls undertook orofacial and cone-beam computed tomography systems
(CBCT) examinations to identify the initial radiological signs of JIA-induced dentofacial
deformity [42]. The initial radiological signs of dentofacial deformities were found to be
subtle and characterized by minor mandibular asymmetry and occlusal plane steepening.
11. Emerging Techniques for JIA Monitoring and Diagnosis
As outlined in the previous section, imaging plays an important role in assessment
of JIA. However, due to the limitations described, there remains a need to develop novel
diagnostic techniques to further support the clinician’s assessment and provide objective
measures of arthritis. In this section a number of these more prominently reported tech-
niques are reviewed. These are infrared thermal imaging, three-dimensional imaging,
accelerometry, artificial neural networks and fuzzy logic.
11.1. Infrared Thermal Imaging
Infrared radiation is part of the electromagnetic spectrum, covering a wavelength
range from about 700 nanometres to 1 mm. Materials with a temperature above absolute
zero (i.e., 0 Kelvin or −273.15 ◦C) emit infrared radiation. Infrared radiation is invisible to
the human eye and can be separated into near-, mid- and far-infrared. Its applications in
medical diagnosis and monitoring have been increasingly reported [43,44].
Thermal imaging has been investigated for its utility in JIA and RA. It is a harmless
technique that uses infrared radiation to detect temperature changes in tissue abnormali-
ties [44]; hence, it could be used to identify active joint inflammation (arthritis) due to an
increased temperature associated with the inflammatory process. It has been investigated
for use in the identification of joint inflammation in paediatric conditions in both the knee
and ankle [45,46]. A study found that thermal imaging could identify significant tempera-
ture differences in the ankle joint but not in inflamed knee joints, indicating the potential of
thermal imaging for detecting joint inflammation in specific joints [45]. A further study
investigated 20 patients with clinically confirmed knee arthritis and demonstrated that
thermal imaging detected higher temperatures in knees with active inflammation [46]. This
study also demonstrated correlation between thermal and visual imaging data. There is
therefore evidence that thermal imaging has the potential to be an objective tool to assist
with the diagnosis and monitoring of JIA.
11.2. Three-Dimensional Imaging
Three-dimensional (3D) imaging is another tool that has been investigated for diag-
nostic use in JIA. A proof-of-concept study was conducted to determine if 3D imaging and
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thermal imaging could correctly quantify inflammatory changes in joint movement [47].
Both modes of imaging demonstrated quantifiable changes in joint volume and shape and
could also quantify joint changes in response to therapy. Such findings suggest that these
new techniques could provide objective means of detecting and monitoring arthritis. This
proof-of-concept study grouped both JIA and adult arthritis as one condition, so its validity
in JIA requires further investigation. Three-dimensional imaging has also been used to
assess facial morphology to identify TMJ involvement in JIA. Three-dimensional imaging
identified unique morphological features that indicated to the affected side/sides and the
severity of TMJ involvement [48]. This pilot study indicated the use of 3D imaging as a
tool to detect the signs of TMJ involvement in JIA. However, further work is required to
develop this novel imaging technique into a clinically acceptable and useful tool.
11.3. Motion Detection Using Accelerometer and Gyroscope
An accelerometer is a sensor for accurately measuring applied acceleration [49]. Typi-
cally, an accelerometer uses three perpendicular axes, commonly referred to as x, y and z.
It can be based on a number of different transducers that include piezo-electric crystals,
piezo-resistive sensors and variable capacitance. Gyroscopes are also motion sensors that
can be in different forms including optical, ring laser and micro-electromechanical. Micro-
Electro-Mechanical-System (MEMS) gyroscopes measure rate of rotation of an object along
either one, two or three axes [50]. An accelerometer and a gyroscope could be integrated
into a single device called an inertia measurement unit (IMU), thus providing greater
flexibility in movement measurement.
Due to their ability to measure movement, accelerometers and gyroscopes can be
utilized to quantify joint movement. Potentially, these devices could quantify the extent to
which joint inflammation has constrained the movement at an affected joint, by comparing
movement data with normal reference values or an unaffected related joint. For example, to
analyse the extent of movement at the knee joint, an accelerometer can be placed just above
and below the knee, and through trigonometry and calculus, the range of movement as well
as the velocity of movement, and the acceleration and deceleration can be determined [51].
Accelerometry has previously been used as a tool for the investigation of joint range
of movement in gait analysis [52], post-surgery rehabilitation analysis [53] and physical
activity monitoring in RA and JIA [54,55]. Earlier studies have also investigated the use of
acceleration patterns to differentiate knees affected by osteoarthritis and chondromalacia as
well as between rheumatoid arthritis and spondyloarthropathy [56,57]. It is hypothesized
that accelerometry could also be used to objectively assess joints affected by arthritis in JIA.
11.4. Artificial Intelligence and Machine Learning
Artificial intelligence and machine learning encompass a number of techniques that
include artificial neural networks, fuzzy logic, expert systems and genetic algorithms.
Artificial neural networks (ANN) are adaptive systems, consisting of interconnected
processing elements called neurons that learn by interacting with their environment [58].
Each connection in an ANN has an associated weight. The weight values are determined
when the ANN is trained. ANNs simulate the way the human brain processes and analyses
information in a simplified manner. They are trained by being presented with representa-
tive examples of the relevant data. ANNs can be grouped in a number of ways, according
to whether their training is supervised or unsupervised. Multilayer perceptron [59,60] and
Kohonen network (self-organizing map) [61] are examples of supervised and unsupervised
learning ANN, respectively.
Fuzzy logic is a generalization of classical logic that attempts to perform reasoning
by modelling human ways of thinking or reasoning [62]. Unlike crisp sets that require
a measurement to belong to a specific category (set), in fuzzy logic, a measurement can
belong to several sets with different degrees of memberships. Degree of membership has a
continuous range between 0 and 1, with 0 indicating not a member and 1 a full membership.
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Artificial intelligence and machine learning techniques have the ability to filter an
abundance of information and identify clinically relevant details. This could have implica-
tions for their use in diagnosis, management, monitoring and disease risk estimation of a
multitude of disorders, including those seen in rheumatology [63].
Possible applications of machine learning in rheumatology include electronic diagnosis
systems, automatic electronic medical records filtering [64], learnt disease prediction mod-
els [65], interpretation of genetic markers and image recognition [66,67]. It has been theorized
that in the future, machine learning could be utilized to assist rheumatologists in predicting
the course of disease and identifying disease factors, and through reinforcement learning, it
may be able to make treatment propositions [67]. Through these methods, AI could possibly
be used as a tool to support rheumatologists in providing a timely and accurate diagnosis to
help create effective management strategies, and to monitor for flares of inflammation. All
these elements are important in achieving optimum outcomes in JIA. There has been little
research on the use of these techniques specifically applied to JIA; however, they have been
used more broadly in the medical field and in rheumatoid arthritis [68].
AI has been investigated for its application specifically analysing imaging in rheuma-
tology for many years; however, most methods have yet to enter clinical practice [68]. A
certain subtype of AI, called deep learning, has shown potential to interpret images beyond
the human-level of accuracy [68]. Potentially this could be applied to the interpretation
of imaging in JIA in order to improve diagnostic accuracy. Deep learning is a sub-field of
machine learning that uses large neural networks to mimic human decision making [67].
Deep learning has been applied in RA to aid the interpretation of different imaging modali-
ties. For example, it has been shown capable of detecting bone erosions from MRI scans
and identifying patients with RA from healthy subjects from an X-ray of the hand [69].
AI has also been shown to measure the extent of synovitis and allocate a score from
Doppler ultrasound images [66]. However, it is unlikely that AI could replace radiologist
interpretation in the near future, as the generalization of computerized image interpretation
would be extremely difficult in such a broad field. It is more likely that AI could work
with human intelligence as a hybrid solution to improve image assessment [68]. In order
to establish such systems, large amounts of data are needed to train the system, and if
these can only be obtained through human interpretation then there is less to gain. Further
research into methods such as neural networks and alternative reference outcome measures
is required to ascertain if this technology could be employed in routine clinical care within
rheumatology [68].
Although more limited, AI has been explored directly within JIA. It has been used to
create automated patient education dialogues for families of children with JIA. A patient-
led dialogue was created using AI techniques and was evaluated by six rheumatology
specialists who found the dialogue was able to provide accurate, relevant and mostly
complete information [70]. This study demonstrates the potential broader use of AI within
rheumatology to help address some of the gaps in patient education experienced by families
affected by JIA.
Fuzzy logic has gained attention in medical diagnosis and monitoring due to its ability
to model and accurately represent uncertainty. Although we did not find a publication
related to its use specifically in JIA, a study used fuzzy logic to develop a relationship map
between rheumatic-musculoskeletal symptoms to risk factors [71]. A fuzzy logic-based
system has been devised to assist with diagnosis of arthritis [72]. Fuzzy logic models that
could provide diagnostic confidence at different levels for RA were reported [73].
The use of AI in rheumatology, and JIA more specifically, is relatively unexplored.
Artificial intelligence-based systems could potentially perform complex and highly specific
clinical tasks; however, further work is required to develop these systems for routine
clinical use. The importance of an early and accurate diagnosis in JIA makes AI an
attractive potential avenue for future research.
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12. Overall Discussion
With advancements in care, medicines, research and technology there is an ever-
growing desire to achieve earlier diagnosis for children and young people who develop JIA.
JIA is primarily a diagnosis of exclusion and relies upon the subjective history-taking and
clinical examination; therefore, the clinician often relies upon the use of diagnostic imaging
to support decision-making. The traditional options of X-ray, musculoskeletal ultrasound
and CE-MRI scanning, have benefits and limitations and, for X-ray, potential exposure
risks when used periodically. There is the need for innovative, acceptable and accessible
tools to help the clinician confirm or refute a suspicion of subtle joint inflammation early in
the course of JIA.
New innovative techniques can complement traditional methods of JIA diagnosis and
monitoring. The application of accelerometry allows joint movements to be quantified and
thus provide an objective measure of joint restriction. For example, when applied to the knee
joint, the method provides information such as the extent of movement (angle) and movement
features through angular velocity and acceleration measurements. Accelerometry is cost
effective and easy to apply and can be performed at the patient’s home. Machine learning
and AI methods such as artificial neural networks (ANNs), fuzzy logic and expert systems
allow the available patient data to be interpreted and analysed quickly and accurately, thereby
aiding clinicians in making diagnostic decisions in a timelier manner. Fuzzy logic allows
imprecise information to be scientifically analysed and relevant inferencing to be carried out.
Fuzzy logic could be useful in JIA monitoring and diagnosis, as clinical observations are often
imprecise. Extensive data are collected in the medical field, and often the full patient benefit
from this data is not realized, partly because busy clinicians do not have sufficient time to
analyse all the available information. Data can have great value in improving patient care
when correctly processed and analysed. One of the main contributions of AI techniques is
making better use of these data for the benefit of patient care.
This review has demonstrated early signs within research that engineering technolo-
gies including AI can be adapted to support the diagnostic and monitoring needs of
children and young people with JIA. In our experience of conducting research within
the area of thermal imaging, for example, children and young people universally report
their preference of this novel technology to traditional monitoring methods, which can
sometimes generate anxiety [46].
13. Conclusions
Early diagnosis and treatment is increasingly recognized as being essential to improve
disease outcomes for children and young people with JIA. Development of novel applica-
tions of technology offers potential to help clinicians in making early diagnoses and target
available treatments earlier in the course of this disease. Within engineering technology
research, newer monitoring and diagnostic techniques have been shown to potentially
assist with diagnosing and managing arthritis. Techniques of particular current interest
are accelerometry to analyse joint movement and restriction, three-dimensional imaging
to accurately visualize joints, infrared thermal imaging to precisely quantify skin surface
temperature and artificial intelligence to assist clinical precision and decision making.
Within AI, artificial neural networks, deep learning neural networks and fuzzy logic have
gained particular attention recently.
This review has presented evidence on the current status of JIA diagnosis and manage-
ment and provided a summary of current novel tools to assist with the clinical management
of JIA. Further work is needed to develop these promising technologies into clinically use-
ful and acceptable tools to help achieve earlier diagnosis of JIA, and thereby achieve the
better outcomes which existing evidence suggests are possible.
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